EFMC-ISMC Virtual Event 2020

First Time Disclosures & Late Breaking News

 Online    September 7-8, 2020

Programme


EFMC-ISMC Virtual Event 2020 - Day 1

17:00

Opening Address by EFMC President

Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland

17:10

Session Chair

Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland

17:15

Discovery of the AhR Antagonist BAY 2416964; a New Clinical Candidate for Cancer Immunotherapy

Dr Norbert SCHMEES
BAYER PHARMACEUTICALS, Berlin, Germany

17:45

Discovery of AZD8154, a Dual PI3Kγδ Inhibitor, as an Inhaled Treatment for Asthma

Dr Matthew W. D. PERRY
ASTRAZENECA, Gothenburg, Sweden

18:15

The Discovery of BMS-986177/JNJ-70033093; a FXIa Inhibitor for the Prevention and Treatment of Thrombosis

Dr Andrew DILGER
BRISTOL-MYERS SQUIBB, Princeton, United States

18:45

QBW251: a Potent Potentiator of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Channel for Treatment of Respiratory Diseases

Dr Atwood CHEUNG
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States

19:15

Closing Remarks

Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland

19:20

End of Day 1

EFMC-ISMC Virtual Event 2020 - Day 2

16:00

Opening Address by EFMC-ISMC Chairman

Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland

16:10

Session Chair

Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland

16:15

Discovery of SCO-267, a First-in-class GPR40 Full Agonist, as a Promising Candidate for the Treatment of Type 2 Diabetes Mellitus, Obesity, and NASH

Dr Naoyoshi NOGUCHI
SCOHIA PHARMA, INC., Fujisawa, Japan

16:45

The Discovery of LTT462, a Potent ERK Inhibitor for the Treatment of Advanced Solid Tumors Harboring MAPK Pathway Alterations

Dr Wooseok HAN
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Cambridge, United States

17:15

GB1211, the First Orally Available Galectin/Galectin 3 Inhibitor to Be Taken into Clinic as a Potential Treatment for Non Alcoholic Steatohepatitis (NASH)

Dr Fredrik ZETTERBERG
GALECTO BIOTECH, Gothenburg, Sweden

17:45

First Time Disclosure of BI 425809, a GlyT1 Inhibitor for the Treatment of CNS Diseases

Dr Riccardo GIOVANNINI
BOEHRINGER INGELHEIM, Biberach, Germany

18:15

Cannabinoid Receptor 2 Agonists on Their Way to Clinics – How Industrial Drug Discovery and Academic Research Can Cross-Fertilize Each Other

Dr Uwe GRETHER
F. HOFFMANN-LA ROCHE, Basel, Switzerland

18:45

Closing Remarks, EFMC-ISMC 2021 and EFMC Events

Prof. Karl-Heinz ALTMANN
ETH ZÜRICH, Zürich, Switzerland
Dr Yves P. AUBERSON
NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland

19:00

End of the EFMC-ISMC Virtual Event 2020